Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification

1999 ◽  
Vol 32 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Gudrun H Borchert ◽  
Dimitrios N Melegos ◽  
He Yu ◽  
Maurizia Giai ◽  
Riccardo Roagna ◽  
...  
1988 ◽  
Vol 24 (4) ◽  
pp. 597-602 ◽  
Author(s):  
Donatella Beccati ◽  
Nadia Grilli ◽  
Patrizia Schincaglia ◽  
Carlo Naldoni ◽  
Licia Tavolazzi ◽  
...  

1990 ◽  
Vol 26 (3) ◽  
pp. 277-281 ◽  
Author(s):  
Alain Bélanger ◽  
Simon Caron ◽  
Fernand Labrie ◽  
Carlo Naldoni ◽  
Luigi Dogliotti ◽  
...  

1997 ◽  
Vol 43 (8) ◽  
pp. 1365-1371 ◽  
Author(s):  
Eleftherios P Diamandis ◽  
Sheila Nadkarni ◽  
Banani Bhaumik ◽  
Aly Abdelrahman ◽  
Dimitrios N Melegos ◽  
...  

Abstract We developed mouse monoclonal antibodies (Abs) against pepsinogen C with highly purified antigen isolated from gastric mucosa. The Abs were used to construct a two-site sandwich-type assay for pepsinogen C with time-resolved fluorometry as a detection technique. The assay has a detection limit of 0.1 μg/L and is precise (within-run and day-to-day CVs <11%). We used this assay to measure pepsinogen C in seminal plasma, breast cyst fluid, amniotic fluid, male and female serum, serum from patients with prostate cancer, urine, breast tumor cytosolic extracts, breast milk, and cerebrospinal fluid. Highest pepsinogen C concentrations were in seminal plasma, followed by breast cyst fluid and amniotic fluid. We found no correlation between prostate-specific antigen concentrations and concentrations of pepsinogen C in serum of prostate cancer patients, and concluded that this marker is not useful for either diagnosing or monitoring prostatic carcinoma. The availability of a highly sensitive, reliable, and convenient method for quantifying pepsinogen C will allow investigations into the possible diagnostic value of this analyte in various clinical conditions, including benign breast diseases, breast cancer, fertility, and pregnancy.


1994 ◽  
Vol 1 (2) ◽  
pp. 49-55 ◽  
Author(s):  
I Számel ◽  
B Budai ◽  
K Daubner ◽  
J Kralovánszky ◽  
Sz Ottó ◽  
...  

ABSTRACT Gross cystic disease (GCD) of the breast may be associated with a higher risk for the development of breast cancer. High levels of sex steroids, steroid hormone precursors, prolactin and cations have been found in breast cyst fluid (BCF) by several investigators. Accordingly, endocrine parameters and the cationic composition of BCF may be considered as useful characteristics to follow patients bearing macrocysts. In this study we have investigated the concentrations of estradiol (E2), progesterone, testosterone, dehydroepiandrosterone (DHA) and DHA-3-sulfate (DHA-S), prolactin, potassium (K+) and sodium (Na+) in BCF aspirated from 99 women. The mean age of the patients was 49.8 years (range 32-58). The hormone levels were measured by RIA methods; K+ and Na+ were determined by flame photometry. Estradiol, progesterone, testosterone, DHA, DHA-S, prolactin and K+ showed significant accumulation in the BCF compared with their respective serum values. The K+/Na+ ratio proved to be useful in dividing cysts into type I (≥1), type II (<1 but ≥0.1) and type III (<0.1) subgroups. For type I BCF, higher DHA, DHA-S and prolactin concentrations were detected. Linear regression analysis established a highly significant (P<0.001) correlation between the concentrations of E2 and DHA-S (r=0.686), and also between testosterone and DHA-S (r=0.711). These findings indicate that type I BCF might be a marker for 'active' GCD of the breast, and suggest that it may be associated with an increased breast cancer risk, since this group of patients is supposed to have cysts with apocrine metaplasia. It is suggested therefore that when BCF is aspirated, sex steroids, steroid precursors and cations should be routinely measured, and women with type I cysts should be regularly examined.


1990 ◽  
Vol 595 (1 Steroid Forma) ◽  
pp. 464-466 ◽  
Author(s):  
F. Orlandi ◽  
P. Caraci ◽  
B. Puligheddu ◽  
M. Torta ◽  
L. Dogliotti ◽  
...  

1990 ◽  
Vol 595 (1 Steroid Forma) ◽  
pp. 455-458
Author(s):  
O. M. Granata ◽  
F. Arcuri ◽  
E. Fecarotta ◽  
G. Brignone ◽  
L. Blasi ◽  
...  

Cancer ◽  
1983 ◽  
Vol 51 (7) ◽  
pp. 1297-1302 ◽  
Author(s):  
John S. Silva ◽  
Gregory S. Georgiade ◽  
William G. Dilley ◽  
Kenneth S. McCarty ◽  
Samuel A. Wells ◽  
...  

1996 ◽  
Vol 784 (1 Challenges an) ◽  
pp. 542-549 ◽  
Author(s):  
S. ZANARDI ◽  
F. PENSA ◽  
R. TORRISI ◽  
V. DE FRANCHIS ◽  
A. BARRECA ◽  
...  

1999 ◽  
Vol 45 (10) ◽  
pp. 1774-1780 ◽  
Author(s):  
Angeliki Magklara ◽  
Andreas Scorilas ◽  
Carlos López-Otín ◽  
Francisco Vizoso ◽  
Alvaro Ruibal ◽  
...  

Abstract Background: Human glandular kallikrein (hK2) belongs to the serine protease family of enzymes and has high sequence homology with prostate-specific antigen (PSA). The physiological role of hK2 has not as yet been determined, but there is evidence that it can regulate the proteolytic activity of PSA through processing and activating pro-PSA, an inactive precursor. Thus, it is conceivable that these two secreted proteins may coexist in biological fluids. Currently, hK2 is considered an androgen-regulated and prostate-specific protein. Recently, it has been demonstrated that hK2 is expressed in the breast cancer cell line T-47D after stimulation by steroid hormones, and we reported that hK2 can be detected in a subset of breast tumor extracts. These data suggest that hK2 may be expressed in tissues other than the prostate, such as those in which PSA has already been detected. Because hK2 is a secreted protein, it may be present in various biological fluids. Methods: We analyzed milk samples from lactating women, amniotic fluid from pregnant women, and breast cyst fluid from patients with gross breast cystic disease, using a highly sensitive and specific immunoassay for hK2. Results: hK2 was present in all three biological fluids. We suggest that the female breast may produce hK2 and provide evidence that hK2 may have value as an additional marker for the discrimination between type I and type II breast cysts. Conclusions: The female breast produces hK2 in addition to PSA. More studies are necessary to establish the role of this kallikrein in nondiseased breast, gross breast cystic disease, and breast cancer.


Sign in / Sign up

Export Citation Format

Share Document